Erasca, Inc. (ERAS)
NASDAQ: ERAS · Real-Time Price · USD
16.98
-0.08 (-0.47%)
Apr 8, 2026, 3:03 PM EDT - Market open
Erasca Employees
Erasca had 103 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
103
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,209,184
Market Cap
5.28B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 103 | 0 | - |
| Dec 31, 2024 | 103 | -23 | -18.25% |
| Dec 31, 2023 | 126 | -3 | -2.33% |
| Dec 31, 2022 | 129 | 6 | 4.88% |
| Dec 31, 2021 | 123 | 21 | 20.59% |
| Jun 30, 2021 | 102 | - | - |
| Mar 31, 2021 | 102 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Caris Life Sciences | 1,846 |
| PTC Therapeutics | 991 |
| Apellis Pharmaceuticals | 739 |
| Rhythm Pharmaceuticals | 414 |
| Mirum Pharmaceuticals | 372 |
| Xenon Pharmaceuticals | 370 |
| Scholar Rock Holding | 289 |
| Cogent Biosciences | 258 |
ERAS News
- 26 days ago - Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results - GlobeNewsWire
- 4 weeks ago - Erasca Exercises Option to Secure Worldwide Rights for ERAS-0015 Pan-RAS Molecular Glue to Include China, Hong Kong, and Macau - GlobeNewsWire
- 4 weeks ago - Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat - GlobeNewsWire
- 6 weeks ago - Erasca Announces Issuance of a U.S. Patent Covering Pan-KRAS Inhibitor ERAS-4001 - GlobeNewsWire
- 2 months ago - Erasca to Present at Upcoming Conferences in February - GlobeNewsWire
- 2 months ago - Why Is Cancer Drug Developer Erasca Stock Trading Lower Monday? - Benzinga
- 2 months ago - Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 2 months ago - Erasca Announces Pricing of Upsized Public Offering of Common Stock - GlobeNewsWire